ClinicalTrials.gg
RecruitingNCT07860476HYPOSTEOUpdated Oct 9, 2026

Impact of Therapeutic Osteopathy-hypnosis on Cancer Patients.

An interventional study of Osteopathy and Hypnosis in Cancer, sponsored by Institut Rafael. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Institut Rafael · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Started Sep 2026; still recruiting 1 month later.
Updated Oct 9, 2026Primary outcomes revisedInterventions changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Osteopathy is recognized as a beneficial complementary approach for cancer patients. By addressing tissue mobility, circulation, and muscle tension, it helps improve physical comfort, reduce musculoskeletal pain, and foster better functional recovery. Several studies have shown that osteopathy can help reduce pain intensity and improve the quality of life for patients undergoing cancer treatment.

Combining hypnosis with osteopathy could thus optimize treatment outcomes by integrating a holistic approach that addresses both physical and psychological needs. The aim of this study is to evaluate the impact of combined osteopathy and hypnosis treatment compared to osteopathic treatment alone in cancer patients, particularly regarding pain with a strong emotional component.

Read the detailed description

While increasingly effective, cancer treatments are often accompanied by severe side effects, including chronic pain, fatigue, and reduced quality of life. Pain has often a strong emotional component, influenced by anxiety, stress, or the psychological distress inherent in the treatment journey.

Osteopathy is recognized as a beneficial complementary approach for cancer patients. By addressing tissue mobility, circulation, and muscle tension, it helps improve physical comfort, reduce musculoskeletal pain, and foster better functional recovery. Several studies have shown that osteopathy can help reduce pain intensity and improve the quality of life for patients undergoing cancer treatment.

However, pain with a strong emotional component may require a more holistic approach; osteopathy offers gradual benefits that can be optimized by combining it with other complementary therapies, such as hypnosis.

As a complementary therapy, hypnosis is increasingly used for pain and stress management in oncology. It works by modulating pain perception and reducing anxiety, thereby helping patients cope better with their symptoms.

Combining hypnosis with osteopathy could thus optimize treatment outcomes by integrating a holistic approach that addresses both physical and psychological needs. The aim of this study is to evaluate the impact of combined osteopathy and hypnosis treatment compared to osteopathic treatment alone in cancer patients, particularly regarding pain with a strong emotional component. This combined approach could represent a significant step forward in improving the well-being of oncology patients by offering care that is better suited to the multidimensional nature of pain.

This research combining osteopathy and hypnosis could help improve symptoms and quality of life of cancer patients, particularly those suffering from chronic pain, anxiety, fatigue, sleep disturbances, or impaired overall well-being.

The hypothesis is based on available data suggesting that the potential value of osteopathy in managing pain and functional disorders, and the patient's bodily experience and the value of hypnosis in managing anxiety and certain symptoms associated with cancer or its treatments.

Combining these two interventions could allow for a complementary approach addressing the physical, emotional, and cognitive dimensions of the patient's experience. Osteopathy could promote improved mobility, reduced tension, and better body awareness, while hypnosis could help modulate pain perception, reduce anxiety, and strengthen the patient's coping mechanisms regarding the disease and treatments.

Consequently, patients receiving this combined care are expected to show improvements in certain quality-of-life parameters, a reduction in pain intensity or impact, decreased stress or anxiety, and enhanced overall well-being. This study will explore these effects in a population of cancer patients while documenting the feasibility, acceptability, and perceived clinical value of this integrative intervention.

02

Conditions studied

  • Cancer

Keywords

  • osteopathy
  • hypnosis
  • holistic approach
  • integrative medicine
  • cancer
  • cancer care
  • pain management
  • chronic pain
  • supportive care
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 80 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Institut Rafael is the lead sponsor of 6 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years,
  • Patient diagnosed with cancer (currently undergoing treatment or having completed oncological treatment),
  • Experiencing chronic pain (≥ 3 months),
  • Presenting a strong emotional component to the pain: K10 score between 20 and 29,
  • Patient able to attend all visits and follow study procedures,
  • Patient who has provided consent.

Exclusion criteria

Exclusion Criteria:

  • Patients with no emotional distress or with severe distress
  • Sensory (auditory, visual) or cognitive deficits likely to hinder the conduct of hypnosis sessions
  • Patient who has undergone hypnotherapy sessions within the last 3 months
  • Patient unable to provide consent
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Other
    Osteopathy

    Patients assigned to this group will benefit from osteopathy sessions.

    Behavioral: Osteopathy

  • Experimental
    Osteopathy + Hypnosis

    Patients assigned to this group will benefit from supportive care combining osteopathy and hypnosis.

    Behavioral: Osteopathy · Behavioral: Hypnosis

Interventions

  • BehavioralOsteopathy

    An osteopathy session includes a health history chat, physical assessment, hands-on treatment, and aftercare advice.

  • BehavioralHypnosis

    Hypnosis sessions consisted in deep relaxation and focused concentration, delivered by practitioners trained in the therapy.

06

What researchers measure

Primary outcomes

  1. Pain and quality of life

    Change in pain and functional quality of life assessed between baseline (Day 0) and 6 weeks using the Brief Pain Inventory (BPI). • Calculation: The mean (average) of four items measuring pain in the last 24 hours or past week: worst pain, least pain, average pain, and current pain ("pain right now"). (Alternatively, a single item like "worst pain" can be evaluated on its own). • Scale Range: 0 to 10 (0 = "no pain", 10 = "pain as bad as you could imagine"). Cut-offs: 0 - 3: Mild pain, 4 - 6: Moderate pain, 7 - 10: Severe pain

    Time frame: 6 weeks

Secondary outcomes

  1. Emotional distress variation

    Change in emotional distress assessed at baseline, 6 weeks, and 1 month using the K10 psychological distress questionnaire (Kessler). Questions: 10 items. Scale: Each item is rated on a 5-point Likert scale from 1 (none of the time) to 5 (all of the time). Total Score Range: 10 to 50 (calculated by summing all 10 responses). .Results 10 - 15 (Low / Well): Little to no psychological distress; likely within normal limits. 16 - 21 (Moderate Distress): Mild to moderate levels of emotional strain or symptoms. 22 - 29 (High Distress): High level of psychological distress; may indicate a mild-to-moderate mental health disorder requiring attention or early intervention; 30 - 50 (Very High / Severe Distress): Severe psychological distress; strongly indicates a probable serious mental health condition and a need for professional evaluation or specialist referral.

    Time frame: 6 weeks

  2. Patient's experience

    Semi-structured qualitative questionnaire on the experience and perception of the combined treatment, administered one month after the final session

    Time frame: 1 month after final intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2026 (actual). Primary completion is estimated for Sep 2027, 12 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 12 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2026
First posted
Oct 6, 2026
StartActual
Sep 30, 2026
Primary completionEst.
Sep 2027
CompletionEst.
Sep 2028
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Interventions
Changed Osteopathy and hypnosis→Hypnosis
Oct 9, 2026
Primary outcomes
1 description edited
What changed in the outcomes
  • DescriptionPain and quality of life: how it is measured was reworded
Oct 9, 2026
Secondary outcomes
1 description edited
What changed in the outcomes
  • DescriptionEmotional distress variation: how it is measured was reworded
Oct 9, 2026
Registered
First appeared on the registry
Oct 6, 2026
Show all 2 updates
  1. Oct 9, 2026
    Primary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionPain and quality of life: how it is measured was reworded
    Secondary outcomes 1 description edited
    What changed in the outcomes
    • DescriptionEmotional distress variation: how it is measured was reworded
    Interventions Changed Osteopathy and hypnosis→Hypnosis
    + 1 other change: verification date
  2. Oct 6, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07860476
Lead sponsor
Institut Rafael
Collaborators
Hartmann Oncology Radiotherapy Group, France
Responsible party
Sponsor
First posted
Oct 6, 2026
Start date
Sep 30, 2026
Primary completion
Sep 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Oct 9, 2026

Study contacts

Alain TOLEDANO, M.D.
Contact
alain.toledano@horg.fr
+ 33 (0)1 84 00 70 07

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion